Oleuropein-driven reprogramming of the myeloid cell compartment to sensitise tumours to PD-1/PD-L1 blockade strategies.
Ester BlancoNoelia Silva-PilipichAna Isabel BocanegraLuisa ChocarroAntonio ProcopioKarina AusínJoaquín Fernandez-IrigoyenLeticia FernándezNerea RazquinAna IgeaMaider GarnicaMiriam EchaideHugo ArasanzRuth VeraDavid EscorsCristian SmerdouGrazyna KochanPublished in: British journal of cancer (2024)
Oleuropein significantly improves the outcome of PD-1/PD-L1 blockade immunotherapy strategies by reprogramming myeloid cells.